Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug
about
Imiquimod for anogenital warts in non-immunocompromised adultsImiquimod for anogenital warts in non-immunocompromised adultsRationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.Virtual Screening Approaches towards the Discovery of Toll-Like Receptor ModulatorsThe toll-like receptor agonist imiquimod is active against prionsToll Like Receptors Signaling Pathways as a Target for Therapeutic InterventionsIdentification of Adjuvantic Activity of Amphotericin B in a Novel, Multiplexed, Poly-TLR/NLR High-Throughput Screen.Novel treatments for recurrent respiratory papillomatosis.Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment.Therapy of cutaneous human Papillomavirus infections.Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day.Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer.Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonistsMore than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia.Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: a preliminary study.Depigmentation therapies for normal skin in vitiligo universalis.A case of erythroplasia of queyrat treated with imiquimod 5% cream and excision.Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccinationToll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancersRecent advances in diagnosis and therapy of human papillomaviruses.Fighting infection using immunomodulatory agents.Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach.Imiquimod as a dermatological therapy.Analysis of cellular and behavioral responses to imiquimod reveals a unique itch pathway in transient receptor potential vanilloid 1 (TRPV1)-expressing neurons.Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors.Optimizing dendritic cell-based approaches for cancer immunotherapy4-Hydrazinyl-1-isobutyl-1H-imidazo[4,5-c]quinoline.Immune therapy for human papillomaviruses-related cancers.Imiquimod: a potential role in dermatology?Discovery of immunopotentiatory drugs: current and future strategies.Imiquimod; an international update on therapeutic uses in dermatology.Safety, efficacy, and patient acceptability of imiquimod for topical treatment of actinic keratosesEfficacy of an immune modulator in experimental Chlamydia trachomatis infection of the female genital tract.The imidazoquinolines and their place in the therapy of cutaneous disease.A study on the use of imiquimod for the treatment of genital molluscum contagiosum and genital warts in female patients.Immunomodulator-based enhancement of anti smallpox immune responses.1-Isobutyl-4-meth-oxy-1H-imidazo[4,5-c]quinolineEuropean course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts.Viral warts in organ transplant recipients: new aspects in therapy.The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview.
P2860
Q24188125-F42A2CAE-167F-4CFF-AD85-F87FC98FA871Q24201332-8DD60D87-84E1-4040-81D9-EC6A5519CC6BQ27686800-B412D4A3-0943-4A98-8D07-8847529B2506Q28068082-1E3DA951-2117-41B7-AA33-18798B336E93Q28535404-51D6D16D-734B-4E2A-B2E6-7999C944F7B6Q29248835-DAC6466C-1D49-4448-B763-60E3AC5129E9Q30388683-B2D41A71-35C7-4F07-AA21-6492C07C1219Q31099594-C0C80F2F-BD55-4515-A670-F973E775E303Q31125993-EA9EFF60-27D9-4593-BEA1-D5963623F7CAQ31133083-D187C2B1-0F4E-4FF1-ACF9-51FD4C93B4FFQ31934243-ECE26365-B876-42C5-9542-4A8115A44BF6Q33293591-D4F9B169-7367-4545-8087-A0ADDCA64951Q33302568-38E83263-4283-46EC-AA4E-C79336692147Q33520407-77B7584D-08F7-4868-A9A4-BE85F3D7ED44Q33708801-C1F243C9-81C6-4445-8F26-0D918AE43CAFQ33739817-2A3B46C0-F72A-459C-8F78-44727AA27D94Q33817068-FD83EA2A-4577-48A1-93B9-65BC30001E4FQ33864400-F132C122-57EC-42FC-AA53-F9AB28321DA9Q33903112-7421CDED-B4CD-4930-92A0-6A7FD5A59875Q34074998-9EB97F2D-2B9A-41FA-9066-6E092C9F7C0BQ34103603-E94C8161-78D2-41B9-9B96-77F923CE729BQ34299210-909A0FB7-E012-47AE-B810-8EE87332EC0EQ34546035-16FFD8D3-7E0E-43A4-8BB8-46D29A742A98Q34602853-788EEB9C-26FF-4E9F-8E4F-647BDA5C6DAEQ34624683-BC4070D6-2527-4589-A09B-0DA5018E4075Q34637535-6F6E8D50-4E26-4336-90E0-47C2A29CC98FQ34637581-608A4DF8-A49A-45E0-A3A2-8A9629858745Q34657561-E10584FF-2B67-4766-B136-F8581C442FB5Q34722728-76D54298-6B6E-41BD-BA2E-7B284007A940Q35009482-3E4146D1-775F-4810-99C9-879B0E3B1D7BQ35009563-E172669D-4B6D-4A5A-90B1-4B496414765EQ35044103-610BD0F7-915B-484F-8BD3-D4BAC03DEFE4Q35056798-71023D18-A257-4C43-9CC5-2C37FF9E9CDEQ35164704-4A2C4AF8-166D-45F9-8F82-0BD40A6E086BQ35199570-B49DEC16-42D0-41B9-AD80-AD5ED7EE81F4Q35391402-62F3496C-B2A4-4FF8-9B22-0EECFBC92753Q35438595-149E0A67-9BDD-42F2-8C01-966E51E8E1F2Q35528570-FBEC4E7C-0BCF-4512-A0E3-1D10A5356242Q35583156-EAB6DBDB-72AA-4D91-82F0-FAD95068B8D3Q35583168-B2C29C97-BAF2-4ABD-B22C-D069107AED99
P2860
Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Review Article Imiquimod appli ...... modifier and new class of drug
@ast
Review Article Imiquimod appli ...... modifier and new class of drug
@en
type
label
Review Article Imiquimod appli ...... modifier and new class of drug
@ast
Review Article Imiquimod appli ...... modifier and new class of drug
@en
prefLabel
Review Article Imiquimod appli ...... modifier and new class of drug
@ast
Review Article Imiquimod appli ...... modifier and new class of drug
@en
P2093
P3181
P1476
Review Article Imiquimod appli ...... modifier and new class of drug
@en
P2093
P3181
P356
10.1016/S0192-0561(98)00068-X
P577
1999-01-01T00:00:00Z